Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov 29;24(12):2494-2500.
doi: 10.1093/ibd/izy160.

Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis

Uma Mahadevan  1 , Marla C Dubinsky  2 , Chinyu Su  3 , Nervin Lawendy  3 , Thomas V Jones  3 , Amy Marren  3 , Haiying Zhang  3 , Daniela Graham  4 , Megan E B Clowse  5 , Steven R Feldman  6 , Daniel C Baumgart  7
Affiliations

Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis

Uma Mahadevan et al. Inflamm Bowel Dis. .

Abstract

Background: Active inflammatory bowel disease increases the risk of adverse pregnancy outcomes. Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). As a small molecule, tofacitinib is likely to cross the placental barrier; however, information on the effects of tofacitinib on pregnancy outcomes is limited. We report pregnancy and newborn outcomes among patients in UC clinical studies with prenatal (maternal/paternal) exposure to tofacitinib.

Methods: Pregnancies with maternal/paternal exposure to tofacitinib were identified and outcomes reported in 5 tofacitinib UC interventional studies (up to March 2017). Outcomes from tofacitinib rheumatoid arthritis (RA), psoriasis, and psoriatic arthritis interventional studies, and RA noninterventional postapproval safety studies, spontaneous adverse event reporting, and registry data are also reported.

Results: Of 1157 patients enrolled in the UC interventional studies, 301 were women of childbearing age. Eleven cases of maternal exposure and 14 cases of paternal exposure to tofacitinib (doses of 5 mg or 10 mg twice daily) before/at the time of conception or during pregnancy were identified. Outcomes included 15 healthy newborns, no fetal deaths, no neonatal deaths, no congenital malformations, 2 spontaneous abortions, and 2 medical terminations. Outcomes across other tofacitinib studies and postmarketing cases were consistent, with a healthy newborn being the most common outcome and no fetal deaths.

Conclusions: Based on the limited data available, pregnancy and newborn outcomes among patients with prenatal (maternal/paternal) exposure to tofacitinib in UC studies appear similar to those reported for other tofacitinib clinical study populations and the general population.

PubMed Disclaimer

Figures

FIGURE 1.
FIGURE 1.
Overview of pregnancy outcomes following maternal (A) and paternal (B) exposure to tofacitinib in the UC, RA, PsO, and PsA clinical studies. Outcomes are categorized as fetal death, congenital malformation, spontaneous abortion, healthy newborn, medical termination, and pending or lost to follow-up.
See this image and copyright information in PMC

References

    1. Cornish J, Tan E, Teare J, et al. . A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut. 2007;56:830–7. - PMC - PubMed
    1. Stephansson O, Larsson H, Pedersen L, et al. . Congenital abnormalities and other birth outcomes in children born to women with ulcerative colitis in Denmark and Sweden. Inflamm Bowel Dis. 2011;17:795–801. - PubMed
    1. de Lima-Karagiannis A, Zelinkova-Detkova Z, van der Woude CJ. The effects of active IBD during pregnancy in the era of novel IBD therapies. Am J Gastroenterol. 2016;111:1305–12. - PubMed
    1. van der Woude CJ, Kolacek S, Dotan I, et al. ; European Crohn’s Colitis Organisation (ECCO) European evidenced-based consensus on reproduction in inflammatory bowel disease. J Crohns Colitis. 2010;4:493–510. - PubMed
    1. Nguyen GC, Seow CH, Maxwell C, et al. ; IBD in Pregnancy Consensus Group; Canadian Association of Gastroenterology The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy. Gastroenterology. 2016;150:734–57.e1. - PubMed

Publication types